NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 285)
Posted On: 09/14/2021 3:48:45 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs and saving patients’ lives,” reads a recent article. This agreement comes after AnPac Bio’s partnership with Advanced Life Therapeutics Co. Ltd to design, fabricate, test and optimize key components of a cancer treatment device. “AnPac Bio is in the later stages of cooperation and partnership discussions with multiple major corporations in the medical industry aimed at increasing commercial CDA-based cancer test revenue and broadening a product pipeline for itself and its partners.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs and saving patients’ lives,” reads a recent article. This agreement comes after AnPac Bio’s partnership with Advanced Life Therapeutics Co. Ltd to design, fabricate, test and optimize key components of a cancer treatment device. “AnPac Bio is in the later stages of cooperation and partnership discussions with multiple major corporations in the medical industry aimed at increasing commercial CDA-based cancer test revenue and broadening a product pipeline for itself and its partners.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)